© 2020 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.
Formulary
Survey: How payers use nonpayer generated data to make formulary decisions
October 19, 2017
External, non-payer generated data can inform formulary decision-making-if payers know their strengths and weaknesses.
Three Orphan Drug Program problems and how the FDA plans to fix them
October 11, 2017
Recently, FDA Commissioner Scott Gottlieb announced the FDA will move to close loopholes in the Orphan Drug Program. Here’s what you need to know.
Top considerations when determining whether to approve expensive drugs
March 30, 2017
Weighing the ethics of approving expensive cancer drugs for patients facing terminal disease is a multifaceted endeavor. Here are some recommendations.
Expedited FDA approval plays dominant role in drug approvals
March 30, 2017
Last year was a banner year for generic drug approvals by the FDA. Find out what’s in store for 2017.
Opinion: More industry-stakeholders play blame game for high drug costs
March 23, 2017
Our policy analyst weighs in on a new drug industry PR campaign that attempts to shift the blame for high drug costs.
How data analytics combats the opioid epidemic
December 25, 2016
Deaths due to opioid abuse have risen sharply-and show no signs of leveling off. Here’s how data analytics can prevent abuse and diversion.
Predictions for biosimilars: How market access will play out
September 09, 2016
Early planning to craft a comprehensive real-world evidence generation strategy can help support the real-world safety and effectiveness of biosimilars.
Antidepressant drug pipeline: What to know
August 29, 2016
There are promising developments in the pipeline for patients with treatment-resistant depression.
Top 4 pharmacy trends healthcare executives should watch
August 28, 2016
Managed Healthcare Executive conducted its first-ever managed care pharmacy survey during the second quarter of 2016 in partnership with Access Market Intelligence. Here’s a look at some of the key findings, with experts weighing in on the results.
Cardiovascular drugs: Current spending, future outlook
May 06, 2016
Cardiovascular drugs are among the most widely used, since their indications are far reaching and address conditions that are prevalent among a large population.